Literature DB >> 22694216

Mechanism of the chaperone-like and antichaperone activities of amyloid fibrils of peptides from αA-crystallin.

Sayuri Fukuhara1, Tatsutoshi Nishigaki, Keisuke Miyata, Nobuhiko Tsuchiya, Tomonori Waku, Naoki Tanaka.   

Abstract

The amyloid fibril of a fragment of the substrate binding site of αA-crystallin (αAC(71-88)) exhibited chaperone-like activity by suppressing the aggregation of alcohol dehydrogenase (ADH) and luciferase. By contrast, the amyloid fibril of the cytotoxic fragment of amyloid β protein (Aβ(25-35)) facilitated the aggregation of the same proteins. We have determined the zeta potential of the amyloid fibril by measuring their electrophoretic mobility to study the effects of the surface charge on the modulation of protein aggregation. The αAC(71-88) amyloid possesses a large negative zeta potential value which is unaffected by the binding of the negatively charged ADH, indicating that the αAC(71-88) amyloid is stable as a colloidal dispersion. By contrast, the Aβ(25-35) amyloid possesses a low zeta potential value, which was significantly reduced with the binding of the negatively charged ADH. The canceling of the surface charge of the amyloid fibril upon substrate binding reduces colloidal stability and thereby facilitates protein aggregation. These results indicate that one of the key factors determining whether amyloid fibrils display chaperone-like or antichaperone activity is their electrostatic interaction with the substrate. The surface of the αAC(71-88) amyloid comprises a hydrophobic environment, and the chaperone-like activity of the αAC(71-88) amyloid is best explained by the reversible substrate binding driven by hydrophobic interactions. On the basis of these findings, we designed variants of amyloid fibrils of αAC(71-88) that prevent protein aggregation associated with neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22694216     DOI: 10.1021/bi3004236

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  5 in total

Review 1.  Therapeutic potential of α-crystallin.

Authors:  Ram H Nagaraj; Rooban B Nahomi; Niklaus H Mueller; Cibin T Raghavan; David A Ammar; J Mark Petrash
Journal:  Biochim Biophys Acta       Date:  2015-04-01

2.  Crown ethers attenuate aggregation of amyloid beta of Alzheimer's disease.

Authors:  Yanli Tian; Xueli Zhang; Yuyan Li; Timothy M Shoup; Xin Teng; David R Elmaleh; Anna Moore; Chongzhao Ran
Journal:  Chem Commun (Camb)       Date:  2014-11-05       Impact factor: 6.222

3.  Epitope alteration by small molecules and applications in drug discovery.

Authors:  Biyue Zhu; Jing Yang; Richard Van; Fan Yang; Yue Yu; Astra Yu; Kathleen Ran; Keyi Yin; Yingxia Liang; Xunuo Shen; Wei Yin; Se Hoon Choi; Ying Lu; Changning Wang; Yihan Shao; Liang Shi; Rudolph E Tanzi; Can Zhang; Yan Cheng; Zhirong Zhang; Chongzhao Ran
Journal:  Chem Sci       Date:  2022-06-28       Impact factor: 9.969

4.  Addition of αA-crystallin sequence 164-173 to a mini-chaperone DFVIFLDVKHFSPEDLT alters the conformation but not the chaperone-like activity.

Authors:  Murugesan Raju; Puttur Santhoshkumar; Leike Xie; K Krishna Sharma
Journal:  Biochemistry       Date:  2014-04-14       Impact factor: 3.162

5.  Lys-315 at the Interfaces of Diagonal Subunits of δ-Crystallin Plays a Critical Role in the Reversibility of Folding and Subunit Assembly.

Authors:  Chih-Wei Huang; Hui-Chen Lin; Chi-Yuan Chou; Wei-Chuo Kao; Wei-Yuan Chou; Hwei-Jen Lee
Journal:  PLoS One       Date:  2016-01-05       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.